Anti-Tenascin C antibody [MTn-12] (ab6346)

ab6346 has been referenced in 10 publications.

1. Katz AM et al. Astrocyte-specific expression patterns associated with the PDGF-induced glioma microenvironment. PLoS One 7:e32453 (2012). IF; Mouse. PubMed: 22393407
2. Chiao YA et al. In vivo matrix metalloproteinase-7 substrates identified in the left ventricle post-myocardial infarction using proteomics. J Proteome Res 9:2649-57 (2010). WB; Mouse. PubMed: 20232908
3. Sotiropoulou PA et al. Bcl-2 and accelerated DNA repair mediates resistance of hair follicle bulge stem cells to DNA-damage-induced cell death. Nat Cell Biol 12:572-82 (2010). PubMed: 20473297
4. Zamilpa R et al. Proteomic analysis identifies in vivo candidate matrix metalloproteinase-9 substrates in the left ventricle post-myocardial infarction. Proteomics 10:2214-23 (2010). WB; Mouse. PubMed: 20354994
5. Xiong W et al. Tenascin-C as a prognostic biomarker in osteosarcoma? Chin Med J (Engl) 122:2737-43 (2009). WB; Human. PubMed: 19951606
6. Yasui Y et al. A primary hepatic malignant mesenchymal tumor with myofibrogenic differentiation in a B6C3F1 mouse. Toxicol Pathol 37:244-8 (2009). PubMed: 19332665
7. Bazigou E et al. Integrin-alpha9 is required for fibronectin matrix assembly during lymphatic valve morphogenesis. Dev Cell 17:175-86 (2009). Hot Start PCR, IHC-FoFr; Mouse. PubMed: 19686679
8. De Santis R et al. Low and high tenascin-expressing tumors are efficiently targeted by ST2146 monoclonal antibody. Clin Cancer Res 12:2191-6 (2006). PubMed: 16609034
9. Pannellini T et al. Timely DNA vaccine combined with systemic IL-12 prevents parotid carcinomas before a dominant-negative p53 makes their growth independent of HER-2/neu expression. J Immunol 176:7695-703 (2006). IHC-P; Mouse. PubMed: 16751417
10. Galiè M et al. Mammary carcinoma provides highly tumourigenic and invasive reactive stromal cells. Carcinogenesis 26:1868-78 (2005). PubMed: 15975963